三阴性乳腺癌患者中医体质类型分析及其与TOP2A基因表达的相关性(3)
第1页 |
参见附件。
[3] 王琦,朱燕波,吴承玉,等.中医体质与健康相关生命质量的相关性[J].中国组织工程研究与临床康复,2007,11(49):9946-9960.
[4] 徐巍,卢雯萍.从中医体质学说研究乳腺癌癌前病变[J].中国中医药信息杂志,2006,13(14):90-92.
[5] Goldhirsch A, Wood WC, Coates AS. Strategies for subtypes- dealing with the diversity of breast cancer:highlights of the ST Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Arm Oncol,2011,22(8):1736-1747.
[6] 中华中医药学会.中华中医药学会标准:中医体质分类与判定[M].北京,2009.
[7] 王佳玉.TOP2A基因扩增与乳腺癌含蒽环类药物新辅助化疗疗效的相关性研究[D].北京:北京协和医学院,2011.
[8] 张晶.乳腺癌中医体质类型与分子分型关系的临床研究[D].北京:北京中医药大学,2012.
[9] Hayes DF, Thor A, Dressler L, et al. The caneer and leukemia group:her2 and response to paclitaxel in node-positive breast cancer[J]. N Engl J Med,2007,357:1496-1506.
[10] Brünner N, Ejlertsen B, Gehrmann M, et al. Prediction of responsiveness to adjuvant anthracyclines in high-risk breast cancer patients[J]. ASCO Meeting Abstracts,2009,27(5):597.
[11] Levine MN, Pritchard KI, Bramwell VH, et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorourceil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer:update of National Cancer Institute of Canada Clinical Trials Group Trial MA5[J]. J Clin Oncol,2005,23(22):5166-5170.
[12] O’Malley FP, Chia S, Shepherd LE, et al. Topoisomerase Ⅱ alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node- positive breast cancer (NCIC CTG MA.5)[J]. Breast Cancer Res Treat,2006,100:518.
(收稿日期:2014-04-18)
(修回日期:2014-05-21;编辑:陈静)
您现在查看是摘要介绍页,详见PDF附件。